<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-5 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-5</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-5</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>study_type</strong></td>
                        <td>str</td>
                        <td>Study design/type (e.g., GWAS, candidate gene association, cohort, case-control, family study, Mendelian randomization, meta-analysis, twin study, molecular epidemiology, biomarker study, mechanistic/animal model).</td>
                    </tr>
                    <tr>
                        <td><strong>population_description</strong></td>
                        <td>str</td>
                        <td>Population details relevant to smoker susceptibility (e.g., ancestry/ethnicity, country, age range, sex distribution, smoker-only vs mixed, cases/controls counts, NSCLC vs SCLC).</td>
                    </tr>
                    <tr>
                        <td><strong>smoking_exposure_metrics</strong></td>
                        <td>str</td>
                        <td>How smoking exposure was measured/stratified (e.g., pack-years, cigarettes/day, duration, age at initiation, time since quitting, nicotine dependence, inhalation depth/topography, tar yield, biomarker-verified exposure such as cotinine, NNAL, PAH metabolites). Include cutoffs/categories if reported.</td>
                    </tr>
                    <tr>
                        <td><strong>lung_cancer_outcome_definition</strong></td>
                        <td>str</td>
                        <td>Outcome definition used (incident lung cancer, mortality, histology subtype, stage) and ascertainment method (registry, pathology-confirmed, self-report, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>host_genetic_factors</strong></td>
                        <td>list</td>
                        <td>Genetic variants/genes/loci linked to differential lung cancer risk among smokers (e.g., CHRNA5-CHRNA3-CHRNB4, TERT, TP63, HLA, CYP1A1, GSTM1, GSTT1, NAT2, XRCC1/ERCC2). For each, capture variant identifier if present (rsID), direction of effect, and whether association is in smokers specifically or via smoking intensity.</td>
                    </tr>
                    <tr>
                        <td><strong>gene_environment_interactions</strong></td>
                        <td>list</td>
                        <td>Explicit gene×smoking (or gene×dose) interactions reported. Include interacting factor(s), interaction model (additive/multiplicative), and a brief summary of the finding.</td>
                    </tr>
                    <tr>
                        <td><strong>polygenic_or_risk_scores</strong></td>
                        <td>str</td>
                        <td>Any polygenic risk score (PRS) / genetic risk model used to stratify smokers. Include how many variants, model description, and how risk differs across PRS quantiles/deciles if reported.</td>
                    </tr>
                    <tr>
                        <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                        <td>list</td>
                        <td>Biomarkers relevant to differential internal dose or metabolic activation/detoxification among smokers (e.g., NNAL, PAH metabolites, DNA adducts, 4-ABP adducts). Include tissue (blood/urine/lung), and how levels relate to lung cancer risk.</td>
                    </tr>
                    <tr>
                        <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                        <td>list</td>
                        <td>Mentions of DNA repair capacity/genes, mutagen sensitivity assays, chromosomal aberrations, telomere length, or related measures that predict which smokers develop lung cancer.</td>
                    </tr>
                    <tr>
                        <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                        <td>list</td>
                        <td>Epigenetic markers (e.g., DNA methylation signatures in blood/sputum/airway epithelium, AHRR/F2RL3 smoking methylation markers) or gene expression field-of-injury signatures that stratify smoker risk. Include sample type and reported predictive performance if available.</td>
                    </tr>
                    <tr>
                        <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                        <td>list</td>
                        <td>Comorbidities or lung phenotypes modifying risk among smokers (e.g., COPD, emphysema on CT, chronic bronchitis, fibrosis, airflow limitation, inflammatory markers). Capture whether adjustment/mediation is discussed.</td>
                    </tr>
                    <tr>
                        <td><strong>behavioral_and_social_modifiers</strong></td>
                        <td>list</td>
                        <td>Non-biological modifiers that may explain differences among smokers (e.g., quitting behavior, socioeconomic status, occupational exposures like asbestos/radon/silica, secondhand smoke, air pollution, diet). Include whether they confound or interact with smoking.</td>
                    </tr>
                    <tr>
                        <td><strong>tumor_molecular_features_in_smokers</strong></td>
                        <td>list</td>
                        <td>Tumor genomic features differing across smokers and potentially explaining susceptibility (e.g., mutational signatures such as SBS4, KRAS/EGFR/TP53 mutation patterns, tumor mutation burden). Include any comparison to smokers without cancer if present (e.g., normal tissue, premalignant lesions).</td>
                    </tr>
                    <tr>
                        <td><strong>risk_estimates_key_results</strong></td>
                        <td>str</td>
                        <td>Key quantitative results relevant to differential risk among smokers (e.g., odds ratio/hazard ratio/risk ratio with 95% CI for a factor, stratified by smoking level when possible). Include comparator groups (e.g., highest vs lowest PRS, COPD vs no COPD, biomarker quartiles).</td>
                    </tr>
                    <tr>
                        <td><strong>predictive_model_performance</strong></td>
                        <td>str</td>
                        <td>If the paper reports prediction/stratification among smokers, extract performance (AUC/c-statistic, sensitivity/specificity, calibration, net reclassification improvement) and what variables are included (smoking only vs smoking+genetics+imaging/biomarkers).</td>
                    </tr>
                    <tr>
                        <td><strong>negative_or_null_findings</strong></td>
                        <td>list</td>
                        <td>Any reported non-associations or failed replications relevant to smoker susceptibility (e.g., candidate gene polymorphism not associated after correction, biomarker not predictive). Include brief context.</td>
                    </tr>
                    <tr>
                        <td><strong>proposed_mechanistic_explanations</strong></td>
                        <td>str</td>
                        <td>Authors' proposed mechanisms for why only some smokers develop lung cancer (e.g., differential internal carcinogen dose, DNA repair capacity, immune surveillance, chronic inflammation/field cancerization). Keep concise and tied to evidence in the paper.</td>
                    </tr>
                    <tr>
                        <td><strong>limitations_and_confounders</strong></td>
                        <td>str</td>
                        <td>Key limitations that bear on interpreting heterogeneity (e.g., exposure misclassification, survivor bias, population stratification, unmeasured occupational exposures, reverse causation, small sample size).</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>